Top Tardive Dyskinesia Treatment Companies

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.88 Billion in 2024 and is poised to grow from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026–2033). 

Tardive dyskinesia treatment providers should focus on investing in R&D to develop new therapeutics and treatments. Working with government organizations and health non-profits can also expand the business scope for market players. Developing treatment with minimal side effects is a key opportunity as per the global tardive dyskinesia treatment market analysis. 'Neurocrine Biosciences, Inc. (U.S.) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'H. Lundbeck A/S (Denmark) ', 'AbbVie Inc. (U.S.) ', 'Otsuka Holdings Co., Ltd. (Japan) ', 'Astellas Pharma Inc. (Japan) ', 'Bausch Health Companies Inc. (Canada) ', 'Sumitomo Pharma America, Inc (U.S.) ', 'Reviva Pharmaceuticals Holdings, Inc. (U.S.) ', 'Acadia Pharmaceuticals Inc. (U.S.) ', 'VANDA PHARMACEUTICALS (U.S.) ', 'Eisai Co., Ltd. (Japan) ', 'Zydus Group (India) ', 'Lilly (U.S.) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Pfizer Inc. (U.S.) ', 'Bristol-Myers Squibb Company (U.S.) ', 'Mallinckrodt (U.S.) '

Regulatory agencies, notably the U.S. Food and Drug Administration (FDA), have adopted expedited pathways for TD treatments, recognizing the unmet medical need. Fast-track designations and priority reviews facilitate quicker market entry for promising therapies. This regulatory support incentivizes pharmaceutical companies to invest in TD drug development and favors the global tardive dyskinesia treatment market outlook as well.

Advancements in VMAT2 Inhibitor Therapies: The development and approval of vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine (Ingrezza) and deutetrabenazine (Austedo), have revolutionized TD treatment. These medications specifically target the underlying mechanisms of TD, offering improved efficacy and safety profiles compared to traditional therapies. The introduction of alternative formulations, like Ingrezza Sprinkle, caters to patients with swallowing difficulties, enhancing treatment adherence. Hence, focusing on advancement of therapies is slated to be a top tardive dyskinesia treatment market trend in the long run.

High prevalence of psychiatric disorders, advanced healthcare infrastructure and the presence of key pharmaceutical players like Neurocrine Biosciences and Teva Pharmaceuticals allows this region to lead global demand. Availability of favorable reimbursement policies and increased awareness initiatives are also helping North America maintain its leading stance across the study period.